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Highlights 
 
• Galf-ase from JHA 19 Streptomyces sp. was subcloned. 
• Recombinant Galf-ase was obtained with a yield of 0.5 mg/litre of culture.  
• Galf-ase exhibits the best reported KM for Galf moiety. 
• Galf-ase can be competitively inhibited by thiogalactofuranosides analogues. 
•  Galf-ase can be envisioned in biocatalysis.  
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Abstract 
Despite the crucial role of the rare galactofuranose (Galf) in many pathogenic micro-
organisms and our increased knowledge of its metabolism, there is still a lack of recombinant 
and efficient galactofuranoside hydrolase available for chemo-enzymatic synthetic purposes 
of specific galactofuranosyl-conjugates. Subcloning of the Galf-ase from JHA 19 
Streptomyces sp. and its further overexpression lead us to the production of this enzyme with 
a yield of 0.5 mg/litre of culture. It exhibits substrate specificity exclusively towards pNP β-D-
Galf, giving a KM value of 250 µM, and the highest enzymatic efficiency ever observed of 14 
mM-1.s-1. It proved to be stable to temperature up to 60°C and to at least 4 freeze-thaw’s 
cycles. Thus, Galf-ase demonstrated to be an efficient and stable biocatalyst with greatly 
improved specificity toward the galactofuranosyl entity, thus paving the way to the further 
development of transglycosylation and thioligation reactions. 
 
Keywords: β-D-galactofuranosidase, Subcloning, Glycoside hydrolase, Thio-β-D-
galactofuranoside Inhibition 
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1. Introduction 
D-Galactose (D-Gal) is extensively distributed in nature as constituent of oligosaccharides and 
glycoconjugates.[1] However, under its furanose form, galactofuranose (Galf) is totally absent 
from mammals, but is present in many pathogenic microorganisms.[2],[3] Indeed, there are 
three main and specific enzymes involved in the biosynthesis and the metabolism of the Galf-
containing molecules[4]: UDP-galactopyranose mutase (UGM),[5] 
galactofuranosyltransferase (GalfT)[6] and galactofuranosidase (Galf-ase).[7] The 
glycobiology of Galf and enzymes involved in its metabolism have thus become attractive 
targets for the development of antimicrobial agents.[8]  
Although the metabolism of β-D-galactofuranosyl conjugates has been extensively studied, 
mostly in infectious microorganisms such as Mycobacteria, Trypanosoma, Leishmania and 
Aspergillus, there are only few reports related to these enzymes, especially Galf-ase. Over the 
past forty years, Galf-ase has been identified as responsible for the degradation of the D-Galf 
containing glycoconjugates.[8] The first Galf-ase identified was an extracellular exo-β-D-
galactofuranosidase (exo-β-D-Galf-ase) isolated and partially purified from Penicillium 
fellutanum (ex-type of Penicillium charlesii) culture filtrates.[7] Although described back in 
1977 and later, several exo- and endo-Galf-ases were purified from the culture supernatants 
and cell lysates of filamentous fungi,[7]-[9] bacteria[10] and protozoa,[11] but the genes 
encoding these enzymes have not been identified and expressed earlier, nor their amino acid 
sequence determined. Therefore, reported chemo-enzymatic procedures in literature all used 
cloned α-L-arabinofuranosidases as biocatalytic tools, based on the structure similarity 
between pNP β-D-Galf 1 and its analogue pNP α-L-Araf 2 (Fig 1.).[12][13][14] However, 
given the poor catalytic efficiency of theses biocatalysts toward pNP β-D-Galf 1, there is still a 
crucial need for the discovery of improved biocatalysts that will allow the community to 
easily access to furanosyl conjugates (and analogues) owing potential biological properties.[3] 
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Fig. 1. Chemical structures of pNP β-D-Galf 1 and its analogue pNP α-L-Araf 2. 
 
Only recently, in 2015, based on the draft genome sequence analysis of soil Gram-positive 
bacteria Streptomyces sp., strain JHA19, an open reading frame that encoded Galf specific 
enzyme was identified and cloned, and the enzyme characterized.[15], [16] Another gene 
coding for a putative Galf-ase was also found later in the genome of Streptomyces sp., strain 
JHA26.[16][17], However this first cloned Galf-ase protein was co-expressed with a large 
fusion NusA[18] (N-utilization substance A) tag as solubility enhancer and two His-tags for 
affinity purification purpose, thus leading to a large protein of around 150 kDa (Figure 
2A).[15] We thus rapidly thought that these multiple tags might hamper i) the overexpression 
of the Galf-ase leading to low yield, and ii) the physico-chemical and enzymatic properties of 
this original biocatalyst. In addition, the obtained low yield of protein was incompatible with 
the development of this biocatalyst. 
In view of the previous research considering Streptomyces Galf-ase investigations,[15] we 
wish to report herein the optimization of the overexpression and the purification to 
homogeneity of recombinant ORF1110 β-D-galactofuranosidase including only one His-tag 
(Figure 2B), with detailed and improved biochemical and kinetic properties, as well as 
preliminary inhibition studies of this enzyme. This Galf-ase will thus constitute the basis for 
the further development of biocatalyzed incorporation of Galf moieties in more complex 
glycoconjugates. 
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Fig. 2. Schematic representation of pET plasmid constructs cloning/expression regions 
bearing Galf-ase gene insert. A) pET-50b(+) plasmid construct ORF coding for N-terminal 
Nus protein and double 6xHis-tagged Galf-ase. B) pET-28a(+) plasmid construct ORF coding 
for N-terminal single peptide 6xHis-tagged Galf-ase. 
 
2. Materials and Methods 
2.1. Biological and chemical reagents 
Restriction enzymes and T4 DNA ligase were purchased from Thermo ScientificTM, E. coli 
RosettaTM (DE3) and plasmid vector pET-28a(+) from Novagen®. All p-nitrophenyl 
monosaccharides (pNP sugars) were purchased from Carbosynth (Compton, UK). 
Galactofuranosides 3-6 were chemically synthesized as previously described.[19][20] All 
other laboratory chemicals used as the starting compounds, reagents and solvents were 
analytical grade purity and commercially available, unless otherwise specified. 
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2.2. Subcloning, overexpression, and protein purification 
Plasmid construct pET-50b(+), encoding wild type Galf-ase gene was digested with EcoRI 
and HindIII restriction enzymes and the resulting 2.5 kb fragment containing Galf-ase gene 
was agarose-gel purified and ligated into expression vector pET-28a(+) (Novagen®). Ligation 
was verified by restriction enzyme analysis, and the gene sequence integrity was confirmed 
by DNA sequencing performed by Eurofins Genomics. E. coli RosettaTM (DE3) (Novagen®) 
expression strain was transformed with Galf-ase encoding pET-28a(+) plasmid construct by 
heat shock method and cultured at 37°C overnight on LB agar plates supplemented with 
chloramphenicol (34 µg/mL) and kanamycin (30 µg/mL). One single positive colony was 
used to inoculate fresh lysogeny broth (LB) (10 mL) supplemented with the same antibiotics 
and cultured overnight with agitation at 37°C. The preculture was then inoculated into LB 
broth (1L) containing corresponding antibiotics and shaker incubated (250 rpm) at 37°C. 
Cells were grown to mid-exponential phase (OD600: 0.6), shortly cooled on ice and protein 
expression was induced by the addition of β-D-thiogalactopyranoside (IPTG) (100 µL; 1 M) 
and left on shaker incubator (250 rpm) for further 16 hours at 15°C. Cells were harvested by 
centrifugation (4255 g, 30 min, 4 °C) and the cell pellets were resuspended in lysis buffer 
solution (1:10 v/v; 100 mM NaCl, 50 mM Tris/HCl pH 8, 1 mM phenylmethanesulfonyl 
fluoride (PMSF), 5% glycerol, 0.1% Triton X-100, lysozyme 1 mg/L). Suspension was 
incubated by stirring for 20 min at 4°C, lysed by three freeze-thaw cycles and subsequently 
sonicated ([2 min on/2 min pause]x3, 50% cycle) on ice. Lysate was centrifuged (30 000 g, 20 
min, 4°C), supernatant filtered (0.45 µm pore filter) and the recombinant protein was then 
purified from the clarified lysates using pre-equilibrated (10 mL; 50 mM Tris, 200 mM NaCl, 
10 mM Imidazole) Thermo Scientific HisPurTM Ni-NTA Chromatography Cartridge (1 mL). 
The bound protein was eluted by an imidazole gradient (10-500 mM) and an aliquot of eluted 
fractions were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
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PAGE) on 8% separating gel according to Laemmli’s method[21], and protein bands were 
visualized by staining with Coomassie Brilliant Blue G250. Fractions containing pure protein 
were collected, concentrated by ultrafiltration (30 000 MWCO, Sartorius Vivaspin® sample 
concentrator) and protein quantity was determined using colorimetric Bio-Rad protein assay 
based on the Bradford dye-binding method, with a bovine serum albumin (BSA) as a 
standard. 
2.3. Substrate specificity through hydrolysis of pNP sugars 
The hydrolysis of 21 pNP-linked monosaccharide substrates (pNP α and β-D-Glc, -Man, -Gal, 
-GlcNAc, -Xyl,-L-Fuc, -L-Ara, pNP α-L-Rha, pNP β-D-GalNAc and pNP β-D-GlcA, and 3 
furanoses namely pNP β-D-Galf, pNP α-L-Araf and pNP β-D-Ribf) was assayed in reaction 
mixture (50 µL) containing purified enzyme (5 µL; 0.053 mg/mL), pNP monosaccharide 
substrates (5 µL; 10 mM), buffer (8 µL; 0.1 M Citric acid/0.2 M Na2HPO4 pH 4.5) and water 
(32 µL). Residual spontaneous hydrolysis of the substrate was determined on sample 
containing H2O instead of enzyme. For paranitrophenol (pNP) containing substrates, after 20 
min of incubation at 30°C, 150 µL of sodium carbonate 1 M were added, and produced pNP 
(ɛ405 = 19 500 M−1cm−1) was quantified by absorbance measurement at 405 nm (Thermo 
Scientific™ Multiskan™ GO). All kinetics parameters were calculated by fitting of saturation 
curves (as mean of triplicate measurements) with standard Michaelis-Menten equation, using 
Prism 6 (GraphPad). One unit (U) of enzyme activity was defined as the amount of enzyme 
required to liberate 1 µmol of pNP per min. 
2.4. Effects of pH and temperature 
The optimum pH was determined by incubating the enzyme in various pH adjusted buffers 
(0.1 M Citric acid/HCl pH 2; 0.1 M Citric acid/0.2 M Na2HPO4 pH 2.5 – 6.5; 0.1 M Tris/HCl 
pH 7 – 8; 0.1 M Tris/NaOH, pH 8.5; 0.1 M Glycine/NaOH pH 9 – 9.5). The assays were 
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performed separately in each buffer system containing purified enzyme (5 µL; 0.05 mg/mL), 
pNP β-D-Galf substrate (5 µL; 10 mM), buffer (8 µL; pH 2 – 9.5) and water (32 µL). After 20 
min of incubation at 30°C (water bath), reaction was terminated (150 µL; 1 M Na2CO3) and 
absorbance (405 nm) of released pNP was measured using spectrophotometer (Thermo 
Scientific™ Multiskan™ GO). All the reactions were assayed in triplicate and absorbance 
values were corrected for the spontaneous hydrolysis of the substrate.  
The effect of temperature on the enzyme activity was investigated at temperatures ranging 
from 10 to 80°C. The reaction mixtures (50 µL), containing purified enzyme (5 µL; 0.05 
mg/mL), pNP β-D-Galf substrate (5 µL; 10 mM), buffer (8 µL; 0.1 M Citric acid/0.2 M 
Na2HPO4 pH 4.5) and water (32 µL), were incubated 20 min in thermocycler (Esco Swift 
MiniPro Thermal Cycler). Afterwards, reactions were stopped (150 µL; 1 M Na2CO3). Then, 
the  absorbance (405 nm) of released pNP was measured (Thermo Scientific™ Multiskan™ 
GO) and values were corrected for the spontaneous hydrolysis of the substrate. All the 
reactions were assayed in triplicate and absorbance values were corrected for the spontaneous 
hydrolysis of the substrate. 
2.5. Effect of freeze-thaw cycles 
Three samples (100 µL), containing previously purified enzyme (50 µL; 0.235 mg/mL) 
different concentrations of glycerol (0 %, 10%, 20%) and water, were prepared. The samples 
were precooled on ice (30 min), frozen at -20°C and were removed from -20°C after four 
days, thawed on ice (30 min) and the enzymatic activity of a sample aliquot (10 µL) was 
assayed in reaction mixture (200 µL) containing pNP β-D-Galf substrate (20 µL; 10 mM), 
buffer (35 µL; 0.1 M citric acid/0.2 M Na2HPO4 pH 4.5) and water (135 µL) at 37°C (water 
bath), during 10 min, according to previously described enzymatic activity protocol. This 
predefined freeze and thaw procedure and activity assessment were repeated in four cycles 
within four days interval. Activity recovery was expressed as a percentage of the activity prior 
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to freezing. All the reactions were assayed separately in duplicate and absorbance values were 
corrected for the spontaneous hydrolysis of the substrate. 
2.6. Kinetic studies 
Kinetic parameters were determined with pNP β-D-Galf as a substrate in different 
concentration ranges (0.01 mM-5 mM). The reaction (200 µL) containing buffer (20 µL; 0.1 
M citric acid/0.2 M Na2HPO4 pH 4.5) and water, if required, was started by addition of the 
enzyme (2 µL; 0.13 mg/mL) and after 20 min of incubation at 37°C (water bath), reaction was 
terminated (100 µL; 1 M Na2CO3) and absorbance (405 nm) of released pNP was measured. 
All the reactions were assayed in triplicate and absorbance values were corrected for the 
spontaneous hydrolysis of the substrate. The kinetic parameters (KM, Vm, kcat) were calculated 
using GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA). 
2.7. Inhibition studies 
IC50 assay was performed in the presence of different concentration ranges of inhibitors 3 – 6 
(0.1 mM-7 mM), pNP β-D-Galf substrate (3.75 µL; 10 mM), buffer (20 µL; citric 
acid/Na2HPO4, pH 4.5) and water. The reaction (150 µL) was started by addition of the 
enzyme (11.2 µL; 0.067 mg/mL), and after 20 min of incubation at 37°C (water bath), 
reaction was terminated (100 µL; 1 M Na2CO3) and absorbance of released pNP was 
measured (405 nm). Control enzyme activity reactions were carried out and absorbance values 
were corrected for the spontaneous hydrolysis of the substrate. The type of inhibition for 4 
was tested in the presence of different concentration ranges of pNP β-D-Galf substrate (0.05 
mM-1 mM) and with different concentrations of 4 (0.1 mM-1 mM) in the reaction conditions 
identical to the one previously described. The IC50 value for each inhibitor, the type of the 
inhibition
 
and
 
KI value for 4 were calculated using GraphPad Prism 5 software (GraphPad 
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Software, San Diego, CA, USA). KI value for compounds 3, 5 and 6 was corroborated by the 
following Cheng & Prusoff equation: KI = IC50/(1+[S]/Km).[22] 
 
3. Results and Discussion 
3.1. Subcloning, expression and purification of recombinant Galf-ase 
Plasmid construct pET-50b(+), containing the gene insert coding for β-D-galactofuranosidase 
(Galf-ase), was double digested with EcoRI and HindIII restriction enzymes and the resulting 
2.4 kb Galf-ase gene fragment was excised and purified from agarose-gel. The gene fragment 
was ligated to EcoRI and HindIII linearized pET-28a(+) expression vector. Newly obtained 
plasmid construct was checked for integrity by restriction enzyme analysis and the gene 
sequence was confirmed by DNA sequencing performed by Eurofins Genomics. Plasmid 
construct was transformed into E. coli RosettaTM (DE3) (Novagen®) expression system. Galf-
ase was expressed as soluble recombinant protein bearing only N-terminal peptide 
hexahistidine fusion tag (6xHis-tag). 6xHis-tag facilitated selective recombinant protein 
purification from the bacterial cellular environment by immobilized metal-affinity 
chromatography (IMAC) and, due to its small size, was less likely to interfere with protein 
activity and structure.[23] The 6xHis-tagged Galf-ase was expressed and purified by IMAC 
with a Ni2+ immobilized on a nitrilotriacetic acid matrix (Ni-NTA) column with a yield of 0.5 
mg/litre of bacterial culture.[24],[25] The purified enzyme displayed an intense band on the 
SDS-PAGE gel at an apparent molecular weight (90.3 kDa), consistent with that theoretically 
predicted for the Galf-ase fusion protein (Fig. 3.). This purified Galf-ase was further used for 
biochemical characterization.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 12
 
Fig. 3. SDS-PAGE analysis of Galf-ase after IPTG induction and Ni-NTA chromatography 
purification. Lane 1: protein marker. Lanes 2 & 3: cell’s extract before and after IPTG’s 
induction. Lane 4: purified Galf-ase. 
 
3.2. Substrate specificity  
A Simple one-step colorimetric assay which commonly employs synthetic pNP sugars as 
artificial substrates was used for the assessment of Galf-ase activity. The assay directly 
correlates the release of formed pNP with the hydrolytic activity of tested enzyme and is 
quantified spectrophotometrically at 405 nm. The hydrolytic activity and substrate specificity 
of Galf-ase was screened against 21 commercially available pNP pyranosyl and furanosyl 
substrates at 1 mM (Fig. S1.). The only hydrolysed substrate was pNP β-D-Galf and the Galf-
ase exhibited no hydrolytic activity towards any other of the 20 tested pNP sugars. It is also 
noteworthy that, in these experimental conditions, no activity was observed with the pNP α-L-
araf analogue nor the pNP β-D-Ribf. This result is in total agreement with our previous 
observation.[15]  
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3.3. Temperature and pH properties 
The biochemical properties of purified Galf-ase were investigated with pNP β-D-Galf as a 
substrate in different buffer systems covering the pH intervals between pH 2 and 9.5 and 
temperature intervals between 10 and 80 °C. The optimum pH was comprised in a narrow 
range between 3.5 and 5, significantly decreasing above pH 5. The peak of maximum activity 
is present at pH 4.5 (Fig. 4. Left). Once the optimum pH conditions were established, the 
influence of different temperatures on activity was also measured. For 20 min reactions, the 
optimal temperature was at 60°C with a clear peak of activity (Fig. 4. Right). Temperatures 
above the optimum value resulted in dramatic loss of activity. However, due to practical 
constraints, all the following activity assays were assessed at the physiological temperature of 
37°C. Still, this current Galf-ase biocatalyst exhibits different and improved physico-chemical 
properties toward the previously reported one, with a maximum pH shift from 5.5 to 4.5 and a 
maximum temperature at 60 °C, thus demonstrating the drawback of large fusion tags.[15] 
 
 
Fig. 4. A: Influence of pH on Galf-ase hydrolytic activity towards pNP β-D-Galf 1. B: 
Influence of temperature on Galf-ase hydrolytic activity towards pNP β-D-Galf 1. Error bars 
correspond to the SD of 3 independent measurements. 
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3.4. Freeze-thaw stability 
Galf-ase stability towards multiple freeze and thaw cycles was assayed over a different 
storage conditions, without and in the presence of glycerol (10% and 20%), and throughout 16 
days. Percent of activity was normalized to an initial activity measured for each storage 
condition sample. Galf-ase exhibited stability across all storage conditions tested and 
maintained minimally 70% activity after three cycles (Fig. S2.). After four cycles, Galf-ase 
demonstrated low activity (40%) over all storage conditions and exhibited higher sensitivity 
to inactivation due to multiple freezing. No cryoprotectant was included in this assay to test 
the stability of crude Galf-ase sample which showed to be resistant to inactivation to multiple 
freeze-thaw cycles and retaining 80% activity after three cycles. The addition of glycerol did 
not significantly improve or conserve enzyme stability when compared to one observed in the 
absence of a cryoprotectant. Glycerol is a common cryoprotectant which protects proteins 
from inactivation during freezing and thawing by inhibiting the formation of ice crystals upon 
freezing.[26] Also, it is worth mentioning that the purified enzyme remains fairly active over 
a minimum of three weeks when stored at 4°C without presence of any additives such are 
cryoprotectants, protease inhibitors, reducing agents, metal chelators or antimicrobial agents. 
All together these experiments demonstrate the good stability of the Galf-ase under storage 
condition, which will be highly convenient in order to use it during chemo-enzymatic 
synthesis. 
3.5. Kinetic analysis 
To determine catalytic parameters, Galf-ase activity was further investigated with pNP β-D-
Galf as a substrate at optimum pH and at appropriate temperature. The Galf-ase exhibited 
typical Michaelis-Menten kinetics, with KM value of 250 µM and with kcat value of 3.5 s-1 
giving a kcat/KM of 14 mM-1s-1 (Fig. 5. and table 1). Investigation of kinetic parameters was 
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also extended to pNP α-L-Araf, despite displaying no hydrolysis when screened for substrate 
specificity. The pNP α-L-Araf did not appear to show saturation kinetics with concentrations 
as high as 15 mM (Fig. S3.). The assay did not yield interpretable kinetic parameters since the 
hydrolysis rate was too low to give accurate values. These observations emphasized that Galf-
ase has a really poor Araf-ase activity as it badly recognised the α-L-arabinofuranose moiety, 
thus demonstrating the crucial role of the C-6 hydroxymethyl group in the specific recognition 
by the Galf-ase. In addition, when compared to the recombinant α-L-Araf hydrolases AbfD3 
and Araf51 owing dual specificity for α-L-Araf and β-D-Galf (Table 1, lines 1 & 2), the 
specificity of Galf-ase is incredibly increased toward the hexofuranosyl moiety by a factor of 
about 100-fold. When compared to the only two reported cloned Galf-ases (line 3), from 
Streptomyces sp. strains JHA19 and JHA26, the values are not in the same order of 
magnitude. For Galf-ase JHA19 and JHA26, KM value ranges from 4.4 to 6.8 mM 
respectively,[15] yielding at least a 18-fold lower substrate affinity compared to Galf-ase’s KM 
which is in the µM level (line 4). Finally, the Galf-ase parameters described herein are the 
best reported to date and fully compatible with the development of the specific and efficient 
biocatalyzed incorporation of Galf entities into more complex glycoconjugates. 
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Fig. 5. Michaelis-Menten plot of pNP β-D-Galf 1 hydrolysis reaction catalysed by Galf-ase. 
Mean values and SD error bars were calculated from three independent experiments and from 
a single protein preparation. Error bars correspond to the SD of 3 independent measurements. 
Table 1. KM for synthetic pNP furanoses 1 and 2 toward two different arabinofuranosidases 
and two Galf-ase. 
Enzyme KM for 1 
(mM) 
kcat 
(s-1) 
kcat/KM 
s-1.mM-1 
KM for 2 
(mM) 
kcat 
(s-1) 
kcat/KM 
s-1.mM-1 
AbfD3[12] > 50 15 0.13 3.5 425 122 
Araf51[27][13] 53 12 0.23 0.25 103 412 
JHA 19 & 
26[15] 
4.4 to 6.8 Only VM - - - - 
Galf-ase 0.25 3.5 14 nd nd nd 
nd: not determinable. 
 
3.6. Inhibition studies 
The inhibitory properties of several compounds, i.e. alkyl, thioheteroaryl and thioimidoyl β-D-
galactofuranosides 3-6, were investigated by incubating the enzyme, Galf-ase, in the presence 
of both the substrate pNP β-D-Galf and compounds 3-6 (Fig. S4.). These compounds were 
tested as inhibitors because (i) the glycone part, that is β-D-Galf, is recognized by the active 
site, (ii) the aglycone part is mimicking a carbohydrate moiety and (iii) to probe the stability 
of the thioglyosidic bond.[20] It has been reported previously that alkyl, aryl and heteroaryl 1-
thio-β-D-galactofuranoside derivatives are good inhibitors of exo β-D-galactofuranosidase, 
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isolated from P. fellutanum culture media, and D-galactono-1,4-lactone has been evaluated as 
a reference inhibitor with an IC50 value of 0.02 mM.[28] In our hands, compounds 3, 5 and 6 
showed weak inhibitory activity with IC50 values of 6, 5 and 3 mM respectively, while Galf-
ase was more sensitive to the inhibition by thiogalactofuranoside 4 (Table 2.). This latter 
showed the best inhibition activity, with IC50 value of 0.8 mM. The analysis of the 
Lineweaver–Burk plot (Fig. 6.) indicated that the compound 4 is a competitive inhibitor of the 
Galf-ase with KI value of 0.4 mM. Nevertheless, compared to the only reference L-arabino-
1,4-lactone inhibitor previously probed on Galf-ase,[15] 4 exhibited a 100 times increased in 
inhibition, that can be mostly attributed to its structural analogy to the artificial substrate. 
 
Fig. 6. Lineweaver–Burk plot of competitive inhibition of Galf-ase hydrolytic activity towards 
pNP β-D-Galf by 4. Mean values and SD error bars were calculated from two independent 
experiments and from a single protein preparation. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 18
Table 2. Inhibition studies with galactofuranosides 3-6: determination of their respective IC50 
& KI. 
Compound IC50 
(mM) 
KI 
(mM) 
 
6 3.0 
 
0.8 0.4 
 
5 2.5 
 
3 1.5 
 
4. Conclusion 
In this work, we provided a complete biochemical and kinetic characterization of a subcloned 
recombinant Galf-ase since the recent publication of the first ever cloned one. This enzyme 
was obtained with a reasonable yield of 0.5 mg/liter of culture, and optimally active at pH 4.5 
and at 60°C. It is inhibited by substrate’s structural thio analogue (IC50 = 0.8 mM), which 
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proved to be a moderate competitive inhibitor (KI = 0.4 mM). It exhibits substrate specificity 
exclusively towards pNP β-D-Galf, giving a KM value of 250 µM, and the highest enzymatic 
efficiency ever observed of 14 mM-1.s-1. Since to date, only a few furanosidases have been 
involved in the chemoenzymatic approaches, it would be of great interest to explore and 
evaluate the potential synthetic ability of this enzyme to act both as wild-type in 
transglycosylation[29] or after site-directed mutagenesis as an efficient thioligase[30] in the 
efficient preparation of galactofuranosyl conjugates. Works are currently under progress in 
this direction and results will be reported in due course.  
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